High-Tech Gründerfonds (HTGF) and Bayern Kapital have sold their stakes in Germany-based nanobodies development company ChromoTek to US-based antibody developer Proteintech.
High-Tech Gründerfonds (HTGF) and Bayern Kapital have sold their stakes in Germany-based nanobodies development company ChromoTek to US-based antibody developer Proteintech.